CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH [***]. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.
AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT
This Amendment No. 1 to the Sponsored Research Agreement (Amendment) by and between by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (Penn), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd, 9th Floor, Philadelphia, PA 19104-4310, and Cabaletta Bio, Inc., a Delaware corporation, having a place of business at 2929 Arch Street, Suite 600, Philadelphia, PA 19104 (formerly Tycho Therapeutics, Inc., a Delaware corporation having a place of business at 501 Northwick Lane, Villanova, PA 19085) (Sponsor) is effective as of May 27, 2020 (Amendment Effective Date). Penn and Sponsor may be referred to herein as a Party or, collectively, as Parties.
Penn and Sponsor may be referred to herein as a Party or, collectively, as Parties.
WHEREAS, the Parties entered into a Sponsored Research Agreement dated April 23, 2018 (Agreement). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement; and
WHEREAS, the Parties now desire to amend the Agreement to add additional activities to the Sponsored Research, and to set forth their mutual understandings with respect to the potential license, at a future date, of [***] (as defined below), each as set forth herein; and
WHEREAS, in view of the state of emergency associated with coronavirus, Penn has implemented a plan for prioritizing resources to ensure the safety and welfare of all affected stakeholders, including employees, students, patients, and research subjects. The plan includes a hiatus on the initiation of categories of research that utilize Penn facilities; and
WHEREAS, the Parties are entering into this Agreement so that the Research may be initiated as soon as feasible after the end of the hiatus.
NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows:
| ||1. || |
Definitions. The following definitions will be added to the Agreement as new Sections 1.8,1.9, 1.10:
1.9 Licensed Antigen means [***].